Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Iovance Biotherapeutics, Inc.
  6. Summary
    IOVA   US4622601007

IOVANCE BIOTHERAPEUTICS, INC.

(IOVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/08/2021 06/09/2021 06/10/2021 06/11/2021 06/14/2021 Date
20.59(c) 20.64(c) 23.14(c) 23.45(c) 23.87(c) Last
3 945 096 3 010 053 6 579 891 6 388 263 3 074 742 Volume
+2.03% +0.24% +12.11% +1.34% +1.79% Change
More quotes
Financials (USD)
Sales 2021 - - -
Net income 2021 -306 M - -
Net cash position 2021 405 M - -
P/E ratio 2021 -11,6x
Yield 2021 -
Sales 2022 3,89 M - -
Net income 2022 -336 M - -
Net cash position 2022 152 M - -
P/E ratio 2022 -10,8x
Yield 2022 -
Capitalization 3 649 M 3 649 M -
EV / Sales 2021 -
EV / Sales 2022 899x
Nbr of Employees 241
Free-Float 93,7%
More Financials
Company
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company has developed a shorter manufacturing process for Tumor infiltrating lymphocyte (TIL) therapy known as Generation 2... 
Read more
Sector
Biotechnology & Medical Research
Calendar
06/17 | 02:00pmPresentation
More about the company
Ratings of Iovance Biotherapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about IOVANCE BIOTHERAPEUTICS, INC.
06/14IOVANCE BIOTHERAPEUTICS, INC.  : Change in Directors or Principal Officers, Subm..
AQ
06/10SECTOR UPDATE : Health Care Stocks Helping Push Broader Markets Higher
MT
06/10IOVANCE BIOTHERAPEUTICS  : Shares Rally 11% After Upgrade From JMP Securities
MT
06/10SECTOR UPDATE : Health Care Stocks Leading Broader Thursday Rise for Equities
MT
06/10Today on Wall Street: Prices rise faster than expected in May
06/10ANALYST RECOMMENDATIONS : Ally Financial, Delta Air Lines, IAG, ServiceNow, Unit..
06/10IOVANCE BIOTHERAPEUTICS  : JMP Securities Upgrades Iovance Biotherapeutics to Ma..
MT
06/07SECTOR UPDATE : Health Care Stocks Gain Premarket Monday
MT
06/07IOVANCE BIOTHERAPEUTICS  : Announces Clinical Data for Lifileucel in Combination..
AQ
06/07IOVANCE BIOTHERAPEUTICS  : Says Follow-Up Study Data Show Durability, Depth of R..
MT
06/06Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in A..
GL
06/04IOVANCE BIOTHERAPEUTICS  : Reports Clinical Data On Potential Treatment For Adva..
MT
06/04Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination..
GL
06/03ALPINE IMMUNE SCIENCES  : Appoints Chief Medical Officer
MT
06/01Iovance Biotherapeutics to Present at Upcoming Conferences
GL
More news
News in other languages on IOVANCE BIOTHERAPEUTICS, INC.
2020EN DIRECT DES MARCHES : Thales, Danone, Peugeot, Europcar, Ingenico, Disney, ..
2020STOCK MARKET PARIS : Rester sur le marché ou le quitter, telle est la question
2020EN DIRECT DES MARCHES : Renault, Peugeot, Casino, Vivendi, Bourbon, Gaumont, ..
2020STOCK MARKET PARIS : L'accord commercial Chine / Etats-Unis se profile
More news
Analyst Recommendations on IOVANCE BIOTHERAPEUTICS, INC.
More recommendations
Chart IOVANCE BIOTHERAPEUTICS, INC.
Duration : Period :
Iovance Biotherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IOVANCE BIOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 36,50 $
Last Close Price 23,87 $
Spread / Highest target 114%
Spread / Average Target 52,9%
Spread / Lowest Target -24,6%
EPS Revisions
Managers and Directors
NameTitle
Maria Fardis President, Chief Executive Officer & Director
Jean-Marc Bellemin CFO & Principal Accounting Officer
Iain David Dukes Chairman
Friedrich Graf Finckenstein Chief Medical Officer
Igor P. Bilinsky Chief Operating Officer
Sector and Competitors
1st jan.Capitalization (M$)
IOVANCE BIOTHERAPEUTICS, INC.-48.56%3 584
EXACT SCIENCES CORPORATION-8.00%20 910
GUARDANT HEALTH, INC.-6.16%12 230
BGI GENOMICS CO., LTD.-7.00%7 659
INVITAE CORPORATION-25.33%6 239
ADAPTIVE BIOTECHNOLOGIES CORPORATION-34.45%5 438